Spero Therapeutics earnings release, May 13, 2026

Spero Therapeutics, Inc. (SPRO) · Form 8-K, Item 2.02 · Filed · SEC filing

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

CAMBRIDGE, Mass., May 13, 2026 — Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

“We continue to make solid progress on the tebipenem HBr program alongside our licensing partner, GSK, as we prepare for the FDA’s decision expected in June,” said Esther Rajavelu, President and CEO of Spero Therapeutics. “With GSK’s leadership in anti-infectives, tebipenem HBr, if approved, has the potential to meaningfully improve treatment options for cUTI patients.

Looking ahead, we are positioning the company for the next phase by advancing other corporate activities, including exploring opportunities to grow our portfolio of clinical-stage product candidates.”

Program Update

Tebipenem HBr

Tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of cUTI, including pyelonephritis, to provide an effective oral therapeutic alternative to IV carbapenems. Spero granted GSK an exclusive license to commercialize tebipenem HBr in all territories, except certain Asian territories where Meiji holds development and commercialization rights.

First Quarter 2026 Financial Results

For further details on Spero’s financials, refer to Spero’s Quarterly Report on Form

10-Q, filed with the

U.S. Securities and Exchange Commission (SEC) today.

Government Agency Research Support

The views expressed in this press release are those of the authors and may not reflect the official policy or position of the Department of the Army,

Department of Defense, or the U.S. Government.

Tebipenem HBr Research Support

Select tebipenem HBr studies have been funded in part with federal funds from the Department of Health and Human Services; Administration for Strategic

Preparedness and Response; and Biomedical Advanced Research and Development Authority, under contract number HHSO100201800015C.

About Spero

Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com.

Forward

Looking Statements

Financial statements

Income Statement

Three Months Ended March 31, — (unaudited) (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025$ Change
Revenues:Grant revenue$—763-763
Revenues:Collaboration revenue - related party2585,099-4,841
Revenues:Collaboration revenue12-12
Revenues:Total revenues2585,874-5,616
Operating expenses:Research and development2,90913,606-10,697
Operating expenses:General and administrative4,8876,824-1,937
Operating expenses:Restructuring175-175
Operating expenses:Total operating expenses7,79620,605-12,809
Operating expenses:Loss from operations-7,538-14,7317,193
Operating expenses:Other income (expense)335865-530
Operating expenses:Net loss-7,203-13,8666,663
Operating expenses:Net loss per share attributable to common shareholders per share, basic and diluted-0.13-0.250.12
Operating expenses:Weighted average shares outstanding, basic and diluted:57,281,57055,376,1881,905,382

Balance Sheet

March 31, 2026 — (unaudited) (in thousands)

March 31, 2026December 31, 2025$ Change
Cash and cash equivalents56,12940,26515,864
Other assets2,89228,654-25,762
Total assets59,02168,919-9,898
Total liabilities6,0879,898-3,811
Total stockholder’s equity52,93459,021-6,087
Total liabilities and stockholders’ equity59,02168,919-9,898
Full release

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the potential for tebipenem HBr to meaningfully improve treatment options for cUTI patients, if approved; the anticipated PDUFA date set by the FDA as June 18, 2026; Spero’s exploration of opportunities to expand its portfolio of clinical stage product candidates; the potential of tebipenem HBr to be the first oral carbapenem antibiotic for US patients with cUTI, including pyelonephritis, and to set a new standard of care; the potential receipt of milestone payments under Spero’s license and collaboration agreements; Spero’s estimation that its cash and cash equivalents as of March 31, 2026 will be sufficient to fund operations into 2028; and the potential benefits of any of Spero’s current or future product candidates in treating patients. In some cases, forward-looking statements may be identified by terms such as “may,” “will,” “should,”

“expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,”

“predict,” “potential” or “continue,” the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual results to differ materially from those indicated by such forward looking statements, including whether the FDA will ultimately approve tebipenem

HBr and, if so, the timing of any such approval, taking into account the effects of possible regulatory delays; whether the FDA will require any additional clinical data or place labeling restrictions on the use of tebipenem HBr that would delay approval and/or reduce the commercial prospects of tebipenem HBr; whether a successful commercial launch can be achieved and market acceptance of tebipenem HBr can be established; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; Spero’s reliance on GSK, pursuant to the exclusive GSK License Agreement, to advance development of tebipenem HBr and GSK’s right thereunder to determine, in its sole discretion, whether to further develop and commercialize tebipenem HBr; Spero’s need for additional funding; Spero’s ability to retain key personnel; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Spero explicitly disclaims any obligation to update any forward-looking statements.

Investor Relations Contact:

Shai Biran, PhD

Spero Therapeutics

IR@Sperotherapeutics.com

Media Inquiries: media@sperotherapeutics.com – Tables – Condensed Consolidated Balance Sheet Data

(in thousands)

(unaudited)

Spero Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share data)

(unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Spero Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.